Table 2.
Risk of poor histological response | Risk of treatment failure | |||||
---|---|---|---|---|---|---|
Variation between baseline and pre-surgery(T1-T0) | Poor Resp./ Na | Adjusted Odds Ratio (95%CI)b | P value | Event / Nc | Adjusted Hazard Ratio (95%CI)d | P value |
Serum VEGF (N = 165) | 0.26 | 0.67 | ||||
Q1: −1424 to −284 | 12 / 44 | 1 (ref) | 16 / 44 | 1 (ref) | ||
Q2: −279 to --80 | 16 / 43 | 1.55 (0.57–4.2) | 16 / 45 | 1.13 (0.52–2.5) | ||
Q3: −79 to − + 35 | 12 / 39 | 1.39 (0.46–4.2) | 12 / 45 | 0.98 (0.41–2.3) | ||
Q4: − + 39 to +503 | 19 / 39 | 2.63 (0.97–7.1) | 12 / 45 | 0.69 (0.29–1.7) | ||
Serum bFGF (N = 167) | 0.85 | 0.39 | ||||
Q1: −257 to −2.5 | 15 / 44 | 1 (ref) | 14 / 45 | 1 (ref) | ||
Q2: −2.4 to +0.8 | 14 / 44 | 0.66 (0.21–2.0) | 16 / 45 | 0.66 (0.22–2) | ||
Q3: +0.9 to +7.2 | 15 / 40 | 0.89 (0.3–2.7) | 16 / 45 | 0.45 (0.15–1.3) | ||
Q4: +7.8 to +92 | 15 / 39 | 0.92 (0.3–2.9) | 11 / 45 | 0.45 (0.14–1.4) | ||
Urinary bFGF (N = 73) | 0.67 | 0.20 | ||||
Q1: −14.4 to −2.1 | 5 / 18 | 1 (ref) | 11 / 19 | 1(ref) | ||
Q2: −2.1 to +2.4 | 3 / 17 | 0.48 (0.08–3.0) | 2 / 19 | 0.17 (0.03–0.89) | ||
Q3: +2.6 to +12.9 | 5 / 19 | 0.70 (0.13–3.9) | 6 / 20 | 0.54 (0.15–1.9) | ||
Q4: +13.8 to +413 | 7 / 19 | 1.32 (0.30–5.7) | 9 / 19 | 0.51 (0.18–1.5) |
aPoor Resp. / N: number of patients with poor histological response / number of evaluated patients
bAdjusted odds ratios and their 95% confidence intervals were estimated by multivariable logistic regression, including the biomarker level at diagnosis in quartiles. Results were similar when the model also included the treatment arm (with versus without zoledronate)
cEvents / N: number of events in each subset / number of patients
dHazard ratios of treatment failure and their 95% confidence intervals were estimated in Cox models controlling for the treatment group, initial stage and biomarker level at diagnosis in quartiles